Sintica Biotech is currently developing a drug that targets the CD271 receptor (also known as p75^NTR) for the treatment of melanoma, with the aim to address high unmet medical needs like the primary and acquired resistance against currently available therapies. Sintica’s approach involves the induction of apoptosis through the activation of CD271. To this end we have developed a proprietary new chemical entity (SNT001) that has shown promising results in the neutralization of metastasis, both in vitro and in vivo.